Skip to main content

Table 3 Multivariate adjusted risk estimation of different systolic and diastolic blood pressure as well as pulse pressure quartiles for total mortality in total population and those with and without anti-hypertensive medication: Tehran Lipid and Glucose study (1999–2014)

From: Blood pressure components and incident cardiovascular disease and mortality events among Iranian adults with chronic kidney disease during over a decade long follow-up: a prospective cohort study

 

BP category

Model 1

Model 2

 

E/N

HR

(95% CI)

p

HR

(95% CI)

p

Total (N = 1448)

SBP < 120

41/413

1.01

(0.64–1.58)

0.96

1.05

(0.67–1.64)

0.84

 

120 ≤ SBP < 130*

36/260

Ref

  

Ref

  
 

130 ≤ SBP < 140

60/253

1.69

(1.12–2.56)

0.013

1.40

(0.92–2.14)

0.11

 

SBP ≥ 140

168/522

1.84

(1.28–2.64)

0.001

1.72

(1.19–2.48)

0.004

Treated (N = 399)

SBP < 120

12/52

1.55

(0.67–3.62)

0.31

1.79

(0.75–4.26)

0.19

120 ≤ SBP < 130*

10/45

Ref

  

Ref

  

130 ≤ SBP < 140

20/70

1.71

(0.79–3.68)

0.17

1.66

(0.75–3.67)

0.21

SBP ≥ 140

73/232

1.54

(0.79–2.99)

0.2

1.78

(0.9–3.53)

0.1

Untreated (N = 1049)

SBP < 120

29/361

0.92

(0.54–1.56)

0.75

0.92

(0.54–1.57)

0.77

120 ≤ SBP < 130*

26/215

Ref

  

Ref

  

130 ≤ SBP < 140

40/183

1.64

(1.0–2.71)

0.049

1.34

(0.81–2.23)

0.25

SBP ≥ 140

95/290

1.88

(1.21–2.91)

0.005

1.81

(1.16–2.83)

0.009

Total (N = 1448)

DBP < 80

136/640

1.79

(1.22–2.65)

0.003

1.68

(1.13–2.5)

0.01

 

80 ≤ DBP < 85*

32/276

Ref

  

Ref

  
 

85 ≤ DBP < 90

40/194

1.85

(1.16–2.96)

0.009

1.78

(1.12–2.85)

0.015

 

DBP ≥ 90

97/338

2.66

(1.78–3.98)

<0.001

2.77

(1.85–4.15)

<0.001

Treated (N = 399)

DBP < 80

43/120

2.92

(1.42–6.02)

0.004

2.73

1.3–5.7)

0.008

80 ≤ DBP < 85*

9/76

Ref

  

Ref

  

85 ≤ DBP < 90

12/56

1.99

(0.84–4.74)

0.12

2.02

(0.84–4.88)

0.11

DBP ≥ 90

51/147

3.68

(1.81–7.5)

<0.001

4.53

(2.21–9.3)

<0.001

Untreated (N = 1049)

DBP < 80

93/520

1.47

(0.93–2.33)

0.1

1.41

(0.88–2.26)

0.15

80 ≤ DBP < 85*

23/200

Ref

  

Ref

  

85 ≤ DBP < 90

28/138

1.88

(1.08–3.27)

0.025

1.88

(1.07–3.28)

0.027

DBP ≥ 90

46/191

2.25

(1.36–3.72)

0.001

2.17

(1.3–3.61)

0.003

Total (N = 1448)

PP < 39*

28/363

Ref

  

Ref

  

39 ≤ PP < 51

57/382

1.41

(0.9–2.23)

0.13

1.27

(0.8–2.02)

0.3

51 ≤ PP < 65

91/346

1.79

(1.16–2.76)

0.008

1.51

(0.97–2.33)

0.06

PP ≥ 65

129/357

1.94

(1.26–2.97)

0.002

1.71

(1.11–2.63)

0.014

Treated (N = 399)

PP < 49*

24/109

Ref

  

Ref

  

49 ≤ PP < 60

28/94

1.27

(0.72–2.22)

0.4

1.29

(0.73–2.28)

0.34

60 ≤ PP < 74

33/99

1.03

(0.6–1.78)

0.9

0.91

(0.52–1.59)

0.76

PP ≥ 74

30/97

0.88

(0.5–1.54)

0.65

0.84

(0.48–1.48)

0.54

Untreated (N = 1049)

PP < 39*

18/279

Ref

  

Ref

  
 

39 ≤ PP < 48

22/263

0.88

(0.47–1.64)

0.68

0.66

(0.35–1.26)

0.21

 

48 ≤ PP < 61

56/256

1.7

(0.99–2.93)

0.05

1.22

(0.7–2.14)

0.48

 

PP ≥ 61

94/251

2.18

(1.29–3.69)

0.003

1.83

(1.07–3.12)

0.027

  1. Age was adjusted by considering it as the time-scale
  2. Model 1: Adjusted for sex
  3. Model 2: Adjusted for sex, BMI, prevalent CVD, diabetes, hypercholesterolemia, eGFR, smoking and anti-hypertensive medication (only for the total population)
  4. BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, pp pulse pressure, E/N events/N, HR hazard ratio, CI confidence interval
  5. *Reference intervals
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us